DK1848414T3 - Fremgangsmåde til behandling af gefitinib-resistent cancer - Google Patents

Fremgangsmåde til behandling af gefitinib-resistent cancer

Info

Publication number
DK1848414T3
DK1848414T3 DK06720163.2T DK06720163T DK1848414T3 DK 1848414 T3 DK1848414 T3 DK 1848414T3 DK 06720163 T DK06720163 T DK 06720163T DK 1848414 T3 DK1848414 T3 DK 1848414T3
Authority
DK
Denmark
Prior art keywords
cancer
gefitinib
treatment
erlotinib
progression
Prior art date
Application number
DK06720163.2T
Other languages
English (en)
Inventor
Daniel Haber
Jeffrey E Settleman
Eunice L Kwak
Daphne Winifred Bell
Raffaella Sordella
Nadia G Godin-Heymann
Sridhar Krishna Rabindran
Original Assignee
Gen Hospital Corp
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36777922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1848414(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp, Wyeth Llc filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of DK1848414T3 publication Critical patent/DK1848414T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK06720163.2T 2005-02-03 2006-02-02 Fremgangsmåde til behandling af gefitinib-resistent cancer DK1848414T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64948305P 2005-02-03 2005-02-03
US67198905P 2005-04-15 2005-04-15
PCT/US2006/003717 WO2006084058A2 (en) 2005-02-03 2006-02-02 Method for treating gefitinib resistant cancer

Publications (1)

Publication Number Publication Date
DK1848414T3 true DK1848414T3 (da) 2011-07-25

Family

ID=36777922

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06720163.2T DK1848414T3 (da) 2005-02-03 2006-02-02 Fremgangsmåde til behandling af gefitinib-resistent cancer

Country Status (27)

Country Link
US (3) US10603314B2 (da)
EP (1) EP1848414B1 (da)
JP (1) JP2008528695A (da)
KR (1) KR101313702B1 (da)
CN (7) CN113975393A (da)
AT (1) ATE504299T1 (da)
AU (1) AU2006210572B2 (da)
CA (1) CA2596714C (da)
CY (2) CY1111676T1 (da)
DE (1) DE602006021142D1 (da)
DK (1) DK1848414T3 (da)
ES (1) ES2364495T3 (da)
FR (1) FR16C1004I1 (da)
HK (1) HK1105285A1 (da)
HU (1) HUS1600033I1 (da)
IL (3) IL184791A (da)
LU (1) LU93160I2 (da)
MX (1) MX2007009317A (da)
NI (1) NI200700185A (da)
NO (1) NO20074366L (da)
NZ (1) NZ556673A (da)
PL (1) PL1848414T3 (da)
PT (1) PT1848414E (da)
RU (2) RU2405566C9 (da)
SI (1) SI1848414T1 (da)
WO (1) WO2006084058A2 (da)
ZA (1) ZA200706804B (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
ES2586410T3 (es) 2005-02-11 2016-10-14 Memorial Sloan-Kettering Cancer Center Procedimientos y composiciones de detección de un mutante de EGFR resistente a fármacos
WO2006113151A2 (en) * 2005-04-14 2006-10-26 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
EP2340837B1 (en) * 2005-11-11 2017-03-15 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
RU2492864C2 (ru) 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения рака, несущего мутации egfr
CN101516376A (zh) * 2006-09-18 2009-08-26 贝林格尔.英格海姆国际有限公司 用于治疗携带egfr突变的癌症的方法
WO2008121467A2 (en) * 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
JP2010519906A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｅｒｂｂファミリー遺伝子の発現を抑制するための核酸化合物およびその使用
AU2013203111B2 (en) * 2007-04-13 2015-10-08 Beth Israel Deaconess Medical Center, Inc. Methods for treating cancer resistant to erbb therapeutics
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
JP5369183B2 (ja) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
PL2326329T3 (pl) 2008-08-04 2017-07-31 Wyeth Llc Przeciwnowotworowe połączenia 4-anilino-3-cyjanochinolin i kapecytabiny
WO2010117633A1 (en) 2009-04-06 2010-10-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
HUE044629T2 (hu) 2009-07-06 2019-11-28 Boehringer Ingelheim Int Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
CN103702990B (zh) 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
EP2751285B2 (en) * 2011-08-31 2020-04-01 Genentech, Inc. Method for sensitivity testing of a tumour for a egfr kinase inhibitor
US20150064200A1 (en) * 2012-04-04 2015-03-05 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for 6-phosphogluconate dehydrogenase (6-pgd) as a target for lung cancer therapy
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
KR101384686B1 (ko) * 2013-05-28 2014-04-21 주식회사 바이오인프라 Egfr 표적 치료제에 대한 폐암의 치료 반응성을 예측하는 방법
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2015199454A1 (ko) 2014-06-25 2015-12-30 연세대학교 원주산학협력단 3,4,5-트리하이드록시벤조산, 이의 유도체 또는 이의 염을 유효성분으로 포함하는 수용체 티로신 키나아제 저해제 내성 항암제 조성물
WO2016029175A1 (en) * 2014-08-21 2016-02-25 Pharmacyclics Llc Methods for treating egfr mutant disorders
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
US9364469B1 (en) * 2015-08-26 2016-06-14 Macau University Of Science And Technology Identification of a new AMPK activator for treatment of lung cancer
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases
WO2017117474A1 (en) * 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2018157032A1 (en) * 2017-02-26 2018-08-30 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Frequent egfr and ntrk somatic mutations in colorectal cancer (crc) with microsatellite instability (msi)
WO2019178239A1 (en) * 2018-03-13 2019-09-19 Board Of Regents, The University Of Texas System Methods for treatment of cancers with egfr activating mutations
US20210190761A1 (en) * 2019-12-19 2021-06-24 Johnson & Johnson Consumer Inc. Method for Evaluating the Efficacy of a Composition in Reducing the Effects of Cancer Therapeutics on Skin
TWI776584B (zh) * 2020-07-10 2022-09-01 長庚醫療財團法人林口長庚紀念醫院 β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN113234832B (zh) * 2021-06-30 2022-06-03 深圳市狂风生命科技有限公司 人类egfr基因错义突变分子标志物及其在预测靶向抑制剂抗药性中的应用
CN114569617B (zh) * 2022-05-06 2022-07-29 中国农业大学 甲基硒酸作为吉非替尼治疗吉非替尼耐药的非小细胞肺癌增敏剂的新用途

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA2045231A1 (en) * 1990-07-19 1992-01-20 Victor Ling Cell membrane glycoprotein correlated with resistance to platinum-containing antineoplastic agents
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (da) 1992-12-18 1995-08-21 Hoffmann La Roche
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
ZA956029B (en) 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3437685B2 (ja) * 1995-09-12 2003-08-18 株式会社東芝 交直変換装置の制御保護システム
JP4009681B2 (ja) 1995-11-07 2007-11-21 キリンファーマ株式会社 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6426383B1 (en) * 1997-05-28 2002-07-30 Nalco Chemical Company Preparation of water soluble polymer dispersions from vinylamide monomers
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EA004436B1 (ru) 1998-09-29 2004-04-29 Уайт Холдингз Корпорейшн Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
DK1318837T3 (da) * 2000-08-11 2005-01-10 Wyeth Corp Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
BR0208627A (pt) 2001-04-06 2004-03-09 Wyeth Corp Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
NZ529877A (en) 2001-06-01 2006-08-31 Wyeth Corp Antineoplastic combinations
AU2002345670A1 (en) 2001-06-14 2003-01-02 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CN1659145A (zh) 2001-11-27 2005-08-24 惠氏控股公司 作为egf－r和her2激酶抑制剂的3－氰基喹啉
IL162734A0 (en) * 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
AU2003247483A1 (en) * 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
US7384940B2 (en) * 2002-06-05 2008-06-10 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
AU2003248813A1 (en) 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
AU2003256847A1 (en) * 2002-07-26 2004-02-16 Advanced Research And Technology Institute At Indiana University Method of treating cancer
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
EP1594504A4 (en) * 2003-01-23 2008-12-17 T K Signal Ltd NEW IRREVERSIBLE EGF RECEPTOR TYROSINE KINASE INHIBITORS AND THEIR USES FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES
CN1437942A (zh) 2003-02-08 2003-08-27 杭州华卫制药技术开发有限公司 注射用长春瑞滨粉针剂及制备方法
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
RU2005136222A (ru) 2003-04-22 2006-03-20 Уайт (Us) Противоопухолевые комбинации
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
CN1832757A (zh) 2003-08-01 2006-09-13 惠氏控股公司 表皮生长因子受体激酶抑制剂与细胞毒性剂组合在治疗和抑制癌症中的用途
MXPA06001590A (es) 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
AU2003304497B2 (en) 2003-09-15 2010-06-24 Wyeth Llc Substituted quinolines as protein tyrosine kinase enzyme inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
WO2005049021A1 (en) 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
EP1756137A4 (en) 2003-11-05 2007-10-31 Univ Texas DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US7235564B2 (en) * 2003-12-04 2007-06-26 Amr Technology, Inc. Vinorelbine derivatives
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
CN104774931B (zh) * 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
DK1748998T3 (da) 2004-05-28 2010-05-10 Hetero Drugs Ltd Ny stereoselektiv syntese af benzimidazolsulfoxider
WO2005118876A2 (en) * 2004-06-04 2005-12-15 Genentech, Inc. Egfr mutations
MX2007000944A (es) 2004-07-23 2007-04-13 Astrazeneca Ab Metodo para pronosticar la sensibilidad de un tumor a farmacos del receptor erbb.
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
GT200500287A (es) 2004-10-13 2006-04-17 Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
US20080268034A1 (en) 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
WO2006081985A1 (en) 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
EP1851243A2 (en) 2005-02-24 2007-11-07 Amgen, Inc. Epidermal growth factor receptor mutations
CN101163468A (zh) 2005-02-28 2008-04-16 卫材R&D管理有限公司 磺酰胺化合物的新联合用途
WO2006093353A1 (ja) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物
US8105768B2 (en) 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060235006A1 (en) 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
WO2006113151A2 (en) * 2005-04-14 2006-10-26 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
WO2006116016A2 (en) 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
WO2006116514A2 (en) 2005-04-28 2006-11-02 Wyeth Micronized tanaproget, compositions, and methods of preparing the same
RU2007141654A (ru) 2005-05-12 2009-05-20 Пфайзер Инк. (US) Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат
AU2006249600A1 (en) 2005-05-25 2006-11-30 Wyeth Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
WO2006127205A2 (en) * 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
DE102005053679A1 (de) 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
MX2008000666A (es) 2005-07-15 2008-03-13 Wyeth Corp Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato.
EP1925941B1 (en) 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
NZ566387A (en) 2005-10-05 2010-05-28 Astrazeneca Uk Ltd Method to predict or monitor the response of a patient to an ErbB receptor drug by screening for mutations in an ErbB receptor
US20110052570A1 (en) 2005-10-26 2011-03-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
PE20071042A1 (es) * 2005-11-04 2007-10-12 Wyeth Corp Producto farmaceutico que comprende temsirolimus y malato de sunitinib
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
EP2340837B1 (en) 2005-11-11 2017-03-15 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
CA2630833C (en) 2005-11-24 2015-01-06 Aicuris Gmbh & Co. Kg Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
JP2007145745A (ja) 2005-11-25 2007-06-14 Osaka Univ 変異型ＥＧＦＲ下流シグナルを抑制するＳｒｃファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
WO2007075794A2 (en) 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
WO2007095038A2 (en) 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
US20100152198A1 (en) 2006-04-07 2010-06-17 Manley Paul W Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
EP3399450A1 (en) 2006-05-18 2018-11-07 Caris MPI, Inc. System and method for determining individualized medical intervention for a disease state
TW200808728A (en) 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
RU2492864C2 (ru) 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения рака, несущего мутации egfr
EP2077819A4 (en) 2006-09-28 2011-05-25 Follica Inc METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
US20090317456A1 (en) 2006-10-13 2009-12-24 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
CA2672828A1 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
US20100143340A1 (en) 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
CN111643496A (zh) 2006-12-14 2020-09-11 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
EP2124951B1 (en) 2006-12-21 2014-05-21 Vertex Pharmaceuticals Inc. 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
CN101631536A (zh) 2007-01-12 2010-01-20 惠氏公司 片中片组合物
CN104043123B (zh) 2007-01-25 2019-08-13 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
WO2008093878A1 (en) 2007-02-01 2008-08-07 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
EP1978106A1 (en) 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
CN101663584A (zh) 2007-04-19 2010-03-03 威尔斯达特生物制剂公司 未分离的循环癌细胞的Her-2/neu蛋白的检测和治疗
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
ES2584904T3 (es) 2007-09-10 2016-09-30 Boston Biomedical, Inc. Nuevas composiciones y métodos para el tratamiento del cáncer
EP2205076A4 (en) 2007-09-24 2010-12-29 Tragara Pharmaceuticals Inc POLYTHERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DOUBLE INHIBITORS OF EGFR ÝERBB1 AND HER-2 ÝERBB2
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101918579A (zh) 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
BRPI0819218A2 (pt) 2007-11-05 2015-05-05 Puretech Ventures Métodos, estojos e composições para administração de compostos farmacêuticos
CN101185633A (zh) 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼拉替尼缓释植入剂
MX2010006854A (es) 2007-12-18 2010-09-09 Schering Corp Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
ES2398618T3 (es) 2008-02-25 2013-03-20 Nestec S.A. Selección de fármacos para terapia del cáncer de mama utilizando matrices de anticuerpos
WO2009111073A2 (en) 2008-03-06 2009-09-11 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
WO2009142810A2 (en) 2008-03-25 2009-11-26 Schering Corporation Methods for treating or preventing colorectal cancer
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2009126662A1 (en) 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
AU2009237578C1 (en) 2008-04-18 2014-12-04 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
NZ588710A (en) 2008-04-18 2012-12-21 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
PL2271658T3 (pl) 2008-04-18 2017-05-31 Reata Pharmaceuticals, Inc. Przeciwutleniające modulatory zapalenia: c-17 homologowane pochodne kwasu oleanolowego
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
PL2326329T3 (pl) 2008-08-04 2017-07-31 Wyeth Llc Przeciwnowotworowe połączenia 4-anilino-3-cyjanochinolin i kapecytabiny
US20100069340A1 (en) 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
EP2347009A4 (en) 2008-10-14 2012-05-30 Caris Mpi Inc GENE AND GENE EXPRESSED TARGET PROTEINS FOR THE PRESENTATION OF BIOMARKERS AND SIGNATURES BY TUMOR TYPE
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
MX2011004869A (es) 2008-11-07 2011-06-20 Santaris Pharma As Terapia de combinacion selectiva de erbb-3 (her3).
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
KR20110113648A (ko) 2009-02-04 2011-10-17 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제와 함께 성장인자 억제제를 사용한 폐암의 치료
WO2010098627A2 (ko) 2009-02-27 2010-09-02 한올바이오파마주식회사 약제학적 제제
EP3031807A1 (en) 2009-03-11 2016-06-15 Auckland UniServices Limited Prodrug forms of kinase inhibitors and their use in therapy
WO2010117633A1 (en) 2009-04-06 2010-10-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
AR076053A1 (es) 2009-04-14 2011-05-18 Schering Corp Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
SG177309A1 (en) 2009-07-02 2012-02-28 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
KR20110007985A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR20110007984A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
WO2011025269A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025271A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR20110021691A (ko) 2009-08-25 2011-03-04 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
US20110055838A1 (en) 2009-08-28 2011-03-03 Moyes William A Optimized thread scheduling via hardware performance monitoring
CN102665756A (zh) 2009-10-01 2012-09-12 Csl有限公司 费城染色体阳性白血病的治疗方法
EP2498751B1 (en) 2009-11-09 2019-04-03 Wyeth LLC Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
EP3566697A1 (en) 2009-11-09 2019-11-13 Wyeth LLC Tablet formulations of neratinib maleate
CN105999263B (zh) 2009-11-13 2021-06-29 第一三共欧洲有限公司 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
EP3575413A1 (en) 2009-12-11 2019-12-04 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
EP2524231B1 (en) 2010-01-13 2017-06-28 Wyeth LLC A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR

Also Published As

Publication number Publication date
DE602006021142D1 (de) 2011-05-19
US10596162B2 (en) 2020-03-24
WO2006084058A2 (en) 2006-08-10
HK1105285A1 (en) 2008-02-06
PL1848414T3 (pl) 2011-10-31
MX2007009317A (es) 2008-01-30
EP1848414B1 (en) 2011-04-06
CA2596714C (en) 2014-06-17
CY1111676T1 (el) 2015-10-07
US10603314B2 (en) 2020-03-31
CN101155579B (zh) 2012-10-31
IL184791A (en) 2017-05-29
AU2006210572A1 (en) 2006-08-10
BRPI0606839A2 (pt) 2010-03-09
FR16C1004I1 (fr) 2016-09-23
CN102886045A (zh) 2013-01-23
US20100087482A1 (en) 2010-04-08
IL184791A0 (en) 2008-12-29
US20160310482A1 (en) 2016-10-27
CN108421044A (zh) 2018-08-21
NI200700185A (es) 2008-05-06
NZ556673A (en) 2010-03-26
SI1848414T1 (sl) 2011-08-31
CY2016026I1 (el) 2017-04-05
EP1848414A2 (en) 2007-10-31
KR20070107693A (ko) 2007-11-07
PT1848414E (pt) 2011-05-25
KR101313702B1 (ko) 2013-10-04
RU2405566C9 (ru) 2012-04-27
CN113975393A (zh) 2022-01-28
CN108743588A (zh) 2018-11-06
CN113952338A (zh) 2022-01-21
ZA200706804B (en) 2008-10-29
CN113952459A (zh) 2022-01-21
AU2006210572B2 (en) 2011-08-04
WO2006084058A3 (en) 2006-12-14
AU2006210572A2 (en) 2006-08-10
IL259741A (en) 2018-07-31
HUS1600033I1 (hu) 2016-09-28
LU93160I2 (en) 2016-09-26
ES2364495T3 (es) 2011-09-05
ATE504299T1 (de) 2011-04-15
CA2596714A1 (en) 2006-08-10
IL247165A0 (en) 2016-09-29
JP2008528695A (ja) 2008-07-31
CY2016026I2 (el) 2017-04-05
NO20074366L (no) 2007-11-05
US20230226039A1 (en) 2023-07-20
RU2007132902A (ru) 2009-03-10
RU2405566C2 (ru) 2010-12-10
CN101155579A (zh) 2008-04-02
EP1848414A4 (en) 2008-11-26

Similar Documents

Publication Publication Date Title
DK1848414T3 (da) Fremgangsmåde til behandling af gefitinib-resistent cancer
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
EP3311818A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
UA113658C2 (xx) Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання
MX2009010284A (es) Inhibidores de la tirosina-cinasa de bruton.
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
TW200638937A (en) Use of EGFR tyrosinekinase inhibitors for treatment of chronic rhinosinusitis
EA201001773A1 (ru) Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
DK1843771T3 (da) Anvendelse af pyrimidylaminobenzamider til behandling af sygdomme, der responderer på modulation af Tie-2-kinase-aktiviteten
EA200702201A1 (ru) Рофлумиласт для лечения лёгочной гипертензии
MX2012013527A (es) Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas.
EA200970816A1 (ru) Новая лекарственная форма
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
GB2459598A (en) Heterodimers and methods of using them
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
DK1962822T3 (da) Terapi af maligne neoplasier
UA102114U (uk) Спосіб диференційованої гіпотензивної терапії у хворих на гіпертонічну хворобу
ATE544782T1 (de) Behandlung von kachexie